LCM
PBAXU

Lynwood Capital Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Lynwood Capital Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,000
Closed -$252K – 157
2021
Q4 		$252K Buy
+25,000
New +$253K 0.24% 74

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

Lynwood Capital Management's PBAXU Position: Q1 2022 in Review

Lynwood Capital Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q1 2022, closing a stake of 25,000 shares — an estimated $252K sold.

Lynwood Capital Management first reported a position in PBAXU in Q4 2021 and held it in 1 quarter. The position peaked at $252K in Q4 2021. 28 funds tracked by Wall St. Rank hold PBAXU as of Q1 2022.

  • Lynwood Capital Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Lynwood Capital Management sold 25,000 Phoenix Biotech Acquisition Corp. Unit shares in Q1 2022, an estimated $252K.
  • Lynwood Capital Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • Lynwood Capital Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $252K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q1 2022.

Based on Lynwood Capital Management's 13F filing for Q1 2022, filed 5 May 2022.